Daniel Janney

Daniel Janney (board member) discloses dealings in 3 companies, chiefly Krystal Biotech, Inc., Allakos Inc. and Esperion Therapeutics, Inc. Over a trading history stretching from 27 May 2021 to 27 February 2026, the count stands at 9 filings.

Both buying and selling appear: 1 purchase worth €2.4M, against 6 sales worth €15.5M. Netting one side against the other leaves €13.0M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.

The latest filing, published on 3 March 2026, reports an open-market sale of €2.2M in Krystal Biotech, Inc. The last insider purchase was made public on 23 September 2022, 1,486 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.